Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Phyton Granted API CEP Certificate | Contract Pharma

What are you searching for?

Sign in
Breaking News

Phyton Granted API CEP Certificate

Helps alleviate docetaxel shortage through plant cell fermentation process

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Phyton Biotech, a global supplier of paclitaxel and docetaxel API, has been granted a Certificate of suitability to European Pharmacopeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its docetaxel anhydrous API. Phyton is the first North America- or Europe-based contract API supplier to be granted a CEP for docetaxel. Phyton’s docetaxel API is not subject to the current shortage of 10-deacetylbaccatin (10-DAB) starting material because it uses paclitaxel from its own plant cell fermentation facility.
 
Chief technology officer and vice president of business development, Roland Franke, Ph.D., said, “Virtually every other docetaxel API supplier in the world uses 10-DAB as their docetaxel starting material. Unfortunately, docetaxel API is now in short supply because we are in a periodic shortage of 10-DAB, which is derived from yew tree plantations that are subject to climate, environmental, and harvesting issues. Our docetaxel API uses paclitaxel as its starting material, and the paclitaxel we use is via plant cell fermentation that is produced at our own facility near Hamburg, Germany.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics